TARDBP and amyotrophic lateral sclerosis: Using CRISPR-Q<sub>KD</sub>, we achieve effective knockdown of smn1 and simultaneous knockdown of tardbp and tardbpl, modeling spinal muscular atrophy and amyotrophic lateral sclerosis, respectively.